The group’s principal activity is developing biotechnology products. The group markets its products under the tradenames include Oxycyte(TM) and Fluorovent(TM). The group received approval of investigational new drug application for Oxycyte filed with the U.S. Food and Drug Administration. The group operates from the United States.
